Modular Self-Assembly System for Development of Oligomeric, Highly Internalizing and Potent Cytotoxic Conjugates Targeting Fibroblast Growth Factor Receptors

Researchers aimed to develop a modular, self-assembly system for generation of oligomeric cytotoxic conjugates, capable of FGFR1 clustering, for targeting FGFR1-overproducing cancer cells.
[Journal of Biomedical Science]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

Century Therapeutics, a biotechnology company developing iPSC-derived cell therapies in immuno-oncology, and Outpace Bio, announced a research collaboration in CAR engineering.
[Century Therapeutics]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Genome Edited B Cells: A New Frontier in Immune Cell Therapies

Investigators discuss the potential of engineered B cells as a cell therapy, the challenges involved in editing the Ig locus and the advances that are making this possible, and envision future directions for this emerging field of immune cell engineering.
[Molecular Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Engineering-Enhanced CAR T Cells for Improved Cancer Therapy

Scientists discuss the many challenges to CAR T cell therapeutic success and innovations in CAR design and T cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.
[Nature Cancer]
[zotpress userid=” items=’BT77PN7P’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase I Clinical Trial of FT819, the First-Ever iPSC-Derived CAR T-Cell Therapy

Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.
[Fate Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Stemson Therapeutics Secures $15M Series a Funding to Cure Hair Loss

Stemson Therapeutics announced the closing of a $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Stemson’s iPSC based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.
[Stemson Therapeutics]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Theranostic Cells: Emerging Clinical Applications of Synthetic Biology

Ex vivo and in vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer, microbiome dysbiosis and autoimmune and metabolic diseases.
[Nature Reviews Genetics]
[zotpress userid=” items=’HC5X9B6J’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Vita Therapeutics Raises $32 Million in Oversubscribed Series a Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

Vita Therapeutics announced the completion of an oversubscribed $32 million Series A. Vita’s lead therapy, VTA-100, is currently undergoing studies for the treatment of limb-girdle muscular dystrophy. It is designed to be an autologous treatment that combines gene correction and iPSC technology to help repair and replace muscle cells.
[Vita Therapeutics]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

Shoreline Biosciences, Inc. and BeiGene, Ltd. announced a worldwide collaboration to develop and commercialize a portfolio of natural killer (NK)-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies.
[nan]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Targeted Delivery of CRISPR-Cas9 and Transgenes Enables Complex Immune Cell Engineering

The authors developed a one-step strategy using engineered lentiviral particles to introduce Cas9 RNPs and a CAR transgene into primary human T cells without electroporation.
[Cell Reports]
[zotpress userid=’6445218′ items=’D4BE5RZ9′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Is There a Place for CAR-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?

The authors introduce CAR-T cell technology, describe the meaningful achievements of CAR-T cells observed in onco-hematology and discuss preliminary data obtained with CAR-T cells and their derivative constructions in experimental models of autoimmune diseases.
[Arthritis & Rheumatology]
[zotpress userid=” items=’PIFVQ26U’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share